Navigation Links
Drug shows promise in prostate cancer spread to bone
Date:6/7/2011

ANN ARBOR, Mich. A new drug to treat prostate cancer shows early promise, particularly against tumors that have spread to the bone, a multi-site study shows.

The drug Cabozantinib is designed to target mainly two important pathways linked to the growth and spread of prostate cancer. The drug had the most effect on tumors that had spread to the bone.

"Not only did three-quarters of bone scans have partial or complete resolution, but this was accompanied by improvement in bone pain and decreased need for narcotic use," says lead study author Maha Hussain, M.D., FACP, professor of internal medicine and urology and associate director of clinical research at the University Michigan Comprehensive Cancer Center.

Hussain presented the findings at the American Society of Clinical Oncology annual meeting.

The trial enrolled 171 men with metastatic prostate cancer. In more than three-quarters of the men enrolled, cancer had spread to the bone.

Researchers found 76 percent of patients saw some or all of their tumor shrink on bone scans following treatment with Cabozantinib. In addition, among patients who were on narcotics due to bone pain, 67 percent reported less pain and 56 percent either stopped taking narcotics or reduced the dosage. In addition, more than two-thirds of patients had some tumor regressions in areas of spread outside the bone. The treatment effects lasted on average 29 weeks.

The study found moderate side effects from Cabozantinib, including fatigue, gastrointestinal symptoms and high blood pressure.

"What's interesting about this drug is it brings to the table something we haven't seen before. Dramatic improvements in bone scans are unprecedented in this disease. Despite measurable progress, current treatment options for advanced prostate cancer tend to be modest in effect, so adding to and improving these options is a high priority," Hussain says.

Hussain cautions that this
'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. PARTNER shows similar 1-year survival for catheter-based AVR and open AVR in high-risk patients
2. Combination antibody therapy shows promise in metastatic melanoma
3. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
4. Combination therapy shows promise for rare, deadly cancer caused by asbestos
5. Melanoma Vaccine Shows Promise in Trial
6. Violence Doesnt Make TV Shows More Enjoyable for Kids
7. U.S. Southeast Stroke Belt Also Shows Higher Rates of Cognitive Decline
8. Common transplant drug inhibits breast cancer growth, UNC laboratory study shows
9. CDC Report Shows Bacterial Meningitis Cases on the Decline
10. Study shows 19 percent of young adults have high blood pressure
11. Study shows elderly drivers support competency tests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug shows promise in prostate cancer spread to bone 
(Date:8/28/2014)... greater amounts of yellow pigment in your eyes could ... conditions, a new study reports. In a laboratory ... order to test the distance vision of people with ... in their eyes. The volunteers had widely varying ... nutrients lutein and zeaxanthin, according to the researchers, led ...
(Date:8/28/2014)... GreenRushReview.com, a website dedicated to ... “Video” section located at http://www.greenrushreview.com/category/videos/ , which ... cannabis companies in video format. In the site’s ... news clips, interviews, and other short videos discussing ... the videos can also be found on the ...
(Date:8/28/2014)... Alexandria, VA (PRWEB) August 28, 2014 ... Foundation) will interview Stephen Isaacs, the chairperson, president and ... the Foundation’s Meet the Mesothelioma Experts live ... Foundation’s executive director and mesothelioma expert nurse practitioner, ... the interview will be Aduro BioTech’s experimental therapy for ...
(Date:8/28/2014)... PreDiabetes Centers, the nation’s top provider of prediabetes ... help clients and online readers send out summer healthfully ... Ashley developed variations of Roasted Veggie Pizza , ... PreDiabetes Centers Roasted Veggie Pizza recipe is made with ... a cheese substitute–ideal for people who are lactose intolerant ...
(Date:8/28/2014)... 2014 veEDIS Clinical Systems, LLC ... System (EDIS), in Lawrence Medical Center, located in ... to document patient care, veEDIS is a key ... well as the authorized, confidential exchange of patient ... veEDIS technology, designed in accordance with clinical workflows ...
Breaking Medicine News(10 mins):Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 3Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 2Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 3Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 3
... COPD or chronic obstructive pulmonary disease is a ... // and is associated with severe emphysema or ... can reduce the mortality rate and number of ... study conducted by researchers from the University of ...
... say transmission of genital herpes to others is the ... study shows //the drug valacyclovir may significantly reduce the ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ...
... change the way doctors treat certain prostate cancer patients.The ... cancer patient are grade, PSA level and pathologic stage. ... the Gleason grading system or a Gleason score (GS). ... cancer is seven. In a new study, researchers look ...
... A new study shows the drug valacyclovir may significantly ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ... contagious. Participants with herpes were given ...
... since it interferes with eating and drinking. Children are ... the importance of maintaining// their normal fluid intake despite ... tonsillectomy procedure using less energy than the standard electrocautery ... ,During a tonsillectomy using the electrocautery method, a ...
... by researchers say it is a misconception to believe ... housebound people.// ,Researchers examined 150 children and ... vitamin D. Among the participants, all African-American, East African, ... as were all patients younger than 30. Five patients ...
Cached Medicine News:
(Date:8/28/2014)... Kalifornien, 28. August 2014 ... Start der Patientenrekrutierung für eine IDE-Pivot-Studie ... zur Beurteilung der Sicherheit und Wirksamkeit ... Aneurysmen („WEB") bekanntgegeben. Adam Arthur, MD, Dozent ... of Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der ...
(Date:8/28/2014)... ALISO VIEJO, Calif. , Aug. 28, 2014 ... has initiated patient enrollment in an Investigational Device ... and effectiveness of the WEB™ Aneurysm Embolization System ... University of Tennessee Department of Neurosurgery/Semmes-Murphey Clinic and ... first four patients in the study, treating them with ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3
... GNVC ) announced that Adel A.F. Mahmoud, M.D., ... the Company,s Board of Directors at its annual meeting of ... "Drs. Mahmoud and Connor bring a wealth of experience, especially ... expand the breadth and scope of our vaccine programs there ...
... June 22, 2011 Genesis Biopharma, Inc. (OTC/BB: GNBP), ... that it will hold a conference call with the ... Eastern (9:00 a.m. Pacific).  The Company,s Chairman and Chief ... on the business, and discuss the clinical and commercial ...
Cached Medicine Technology:GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 2GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 3GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 4Genesis Biopharma to Hold Business Update Conference Call on June 29 2
Antigenic Free Protein S, ELISA Method...
... Assay for the Quantitative ... Protein S level based ... Va Inhibition by STA© ... free of Protein S; ...
Colorimetric Assay of Protein C Activity by STA© Analyzers. Highly purified extract of Agkistrodon c. contortrix venom for specific activation of protein C, with an activator selected specially ...
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Medicine Products: